Steven L. Hoerter, Chairman, President and CEO of MBX Biosciences, Inc., filed a Form 4 on November 12, 2026, reporting the sale of 4,893 shares of common stock on November 10, 2026, to cover tax obligations arising from the vesting of restricted stock units.
Key Highlights
- Transaction date: 4,893 shares of common stock were disposed of on November 10, 2026, under transaction code S.
- Weighted average sale price: $54.82 per share, with individual sales ranging from $51.52 to $55.29, inclusive, according to the filing.
- Purpose of sale: The filing states the shares were sold "to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement" between Hoerter and the company.
- Direct ownership after transaction: Hoerter directly holds 78,045 shares of common stock following the reported transaction.
- Indirect ownership: An additional 20,000 shares are held indirectly through the Steven L. Hoerter Revocable Trust dated November 2, 2018, of which Hoerter serves as trustee.
- Beneficial ownership disclaimer: The filing states Hoerter "disclaims beneficial ownership except to the extent of any pecuniary interest therein" with respect to the trust shares.
Hoerter's Mandatory Tax-Cover Sale at MBX Biosciences
According to the Form 4 filed with the SEC on November 12, 2026, Steven L. Hoerter, who serves as Chairman, President and CEO of MBX Biosciences, Inc. (NASDAQ:MBX), sold 4,893 shares of common stock on November 10, 2026. The filing identifies the transaction code as S, and attributes the sale specifically to a mandatory sell-to-cover arrangement. The stated purpose is to satisfy tax obligations connected to the vesting of restricted stock units, not a discretionary open-market sale initiated by the reporting person.
The price reported in the filing is a weighted average of $54.82 per share. Individual transactions within the sale occurred at prices ranging from $51.52 to $55.29, inclusive. The filing notes that Hoerter "undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."
Following the transaction, Hoerter directly holds 78,045 shares of MBX Biosciences common stock. He also holds 20,000 shares indirectly through the Steven L. Hoerter Revocable Trust dated November 2, 2018, in his capacity as trustee. The Form 4 was signed by John W. Smither as attorney-in-fact on November 12, 2026.
What Was Disclosed
The filing reports a sale of 4,893 common shares by MBX Biosciences CEO Steven L. Hoerter on November 10, 2026, executed under a mandatory sell-to-cover agreement to satisfy RSU vesting tax obligations, leaving him with 78,045 direct shares and 20,000 indirect trust shares.



Please wait processing your request...